Real‐world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
Akira Takahashi, Naoya Yamazaki, Eiji Nakano, Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Haruki Mizuta, Shunichi Jinnai, Kenta Nakama, Dai Ogata(University of Miyazaki), Keita Tsutsui(Fukuoka University), Yusuke Muto
Cited by 24
Related Papers
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
|Oncotarget|2016|160
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
|Annals of Oncology|2020|140